

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Erik Buntinx  
Serial No. : 10/752,423  
Filed : January 6, 2004  
For : METHOD OF TREATING MENTAL DISORDERS USING D4  
AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR  
PARTIAL AGONISTS  
Art Unit : 1627  
Examiner : Umamaheswari Ramachandran  
Customer No. : 1912  
Confirmation No.: 3783

**COMMUNICATION TO SUBMIT TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Communication is submitted in response to telephonic communications between Examiner Umamaheswari Ramachandran and Alan D. Miller regarding obviousness-type double patenting between the claims of the above-identified patent application and claims of earlier-filed patent family member, U.S. Patent Application No. 10/725,965, filed on December 2, 2003.

EFS  
Confirmation No. 3783  
Applicant: Erik Buntinx  
Serial No.: 10/752,423  
Filed: January 6, 2004  
July 27, 2010 Communication to Submit Terminal Disclaimer  
page 2 of 2

Applicant attaches hereto a Terminal Disclaimer in compliance with 37 C.F.R. §1.321(c) to remove a double patenting rejection over U.S. Patent Application No. 10/725,965.

A fee of \$70.00 is required for a small entity for submitting a Terminal Disclaimer. Authorization is hereby given to charge the \$70.00 fee for submitting the Terminal Disclaimer to Deposit Account No. 01-1785. No additional fee is deemed necessary in connection with the submission of this Communication. However, if any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: July 27, 2010  
New York, New York

By: /Alan D. Miller/  
Alan D. Miller, Reg. No. 42,889